Oncology health literacy
Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma
Few therapies are effective for treating advanced soft tissue sarcoma, so pazopanib quickly became a commonly prescribed therapy once it was approved for STS in April 2012. Although pazopanib is safe and effective, patients must be educated about its administration and side effects.
March 08, 2016
Antiemetics for Nausea and Vomiting Simplified
As oncology nurses, we must have a solid understanding of and a certain comfort level with the use of antiemetics. It seems easy to get stuck in a routine that revolves around one or two drugs for all of our patients. However, antiemetic regimens need to be just as individualized for patients as their chemotherapy regimens.
July 14, 2015
Understand Medication Adherence to Oral Oncology Agents
More than half of new cancer treatment regimens involve an oral route of administration because oral drugs are more manageable and convenient for patients. However, oral medications pose challenges with regard to patient adherence.
April 25, 2015
Outpatient Oncology Drug Series: Doxorubicin Is the Infamous Red Devil
Doxorubicin is a cytotoxic chemotherapy drug and an antitumor antibiotic in the anthracycline group. You’ll see this drug quite a lot In the outpatient setting, and most commonly, you’ll use it to treat patients with breast cancer.
April 10, 2015
Outpatient Oncology Drug Series: Don't Forget Leucovorin Calcium, the Superhero Sidekick
I think it's helpful to be able to educate your patients on the reasons for receiving each individual drug in a combination regimen. Although leucovorin is not a chemotherapy agent or generally used as a stand-alone drug, it certainly is important. Leucovorin has a specific function, and you should be able to explain its purpose.
March 16, 2015
When Should Appetite Stimulants Be Discussed With Patients With Unintended Weight Loss From Cancer Treatment?
Unintended weight loss and anorexia in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life.
January 20, 2015
Outpatient Oncology Drug Series: Paclitaxel Packs a Punch
Oncology nursing is a field in which you are challenged on a regular basis to expand your knowledge because of the constantly changing field of treatments being used. Whether you are new or seasoned, it can be difficult to stay on top of the numerous agents used for varying diagnoses.
December 12, 2014
The Case of the Cannabis Conundrum
Derek is a 20-year-old patient with relapsed acute myeloid leukemia. He will be receiving a bone marrow transplant in the next six days. When discussing Derek’s home medications, he says to the nurse, “I smoke a lot of pot because it helps me feel better about all of this.” Upon further discussion, Derek reveals he started smoking marijuana to relieve nausea. What would you do?
December 02, 2014
Manage Immune-Related Adverse Events Associated With Cancer Immunotherapies
The FDA approved two new immunomodulatory agents, sipuleucel-T and ipilimumab, in 2010 and 2011, respectively. Sipuleucel-T was approved to treat metastatic prostate cancer, and ipilimumab was approved for advanced or metastatic melanoma.
September 09, 2014
Genetics & genomics
Get a Cheat Sheet on Personalized Medicine, Genomics, and Pharmacogenomics in Oncology
Since the concepts of inheritance, genetics, and medical genetics were introduced, researchers have found that many factors other than the presence or absence of a single gene predict disease.
August 12, 2014
Oncology drug research
FDA Approves Ramucirumab for Gastric or Gastroesophageal Junction Adenocarcinoma
On April 21, 2014, the U.S. Food and Drug Administration approved ramucirumab for use as a single agent for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.
April 22, 2014
No Ordinary Pill
Oral agents are changing oncology treatment, and along with it, who’s responsible for the safety of those treatments. “With oral agents, the onus is now primarily on patients and their caregivers,” says ONS member Kathy Leifeste. This is quite a shift from the nurse-administered IV chemotherapy and biotherapy we’ve grown accustomed to.
March 01, 2014
ASH Recommends Wise Choices for Five Hematologic Tests and Treatments
A new list of evidence-based recommendations from the American Society of Hematology helps patients and providers understand which hematology-related tests and treatments pose significant harm and cost if overused and therefore should be avoided.
February 18, 2014
The Names of Targeted Therapies Give Clues to How They Work
I was reading through the program of my granddaughter's dance recital and noticed that there was not a single common name in the first three groups of young dancers. It was as if their parents purposefully decided to come up with the most unique names possible. This is not the case with the family names of targeted cancer drugs.
December 31, 2013
Access to cancer care
Help Rural HCT Recipients Overcome Barriers to Post-Treatment Care
For patients with hematologic malignancies and genetic immune disorders, HCT is a potentially curative treatment. However, because the therapy is so specialized, only select cancer centers with the appropriate expertise, resources, and experiences offer it.
September 10, 2013
FDA Approves Dabrafenib for Unresectable or Metastatic Melanoma
On May 29, 2013, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar™ capsule, GlaxoSmithKline), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
May 30, 2013